NXTC:NASDAQNextCure, Inc. Analysis

NextCure (NXTC) is trading at $9.55, which sits below its 20‑day SMA of $9.77, 50‑day SMA of $10.67 and 200‑day SMA of $9.93, indicating a short‑term price weakness. The RSI of 45.3 suggests neutral momentum, while the MACD line is marginally above its signal (‑0.374 vs ‑0.383) with a tiny positive histogram, flagged as a bullish signal. Volatility is extreme at >107% over the past 30 days and beta is 1.13, pointing to a stock that swings sharply with the market. Current support sits around $8.52 and resistance near $13.18, giving a technical upside of roughly 38% if the stock rebounds.
On the fundamental side, NXTC reports zero revenue, negative EBITDA of $‑54.3 M, and sizable cash burn, resulting in a negative free cash flow of $‑27.1 M and a ROE of ‑1.32%. Nevertheless, the balance sheet is relatively clean with only $3.9 M debt and a price‑to‑book of 0.96, hinting at a valuation discount to book value. The company just received FDA Fast Track designation for its SIM0505 ADC and will present Phase 1 dose‑optimization data at ASCO 2026, a catalyst that could drive the stock toward analyst median price targets of $18‑$19.33, implying >100% upside. Despite the strong analyst “strong buy” consensus, the lack of commercial revenue and high cash‑flow deficit keep the risk profile elevated.